EN
Home/Start here/It's for a family member
Reading path3 guides, in order

Someone in my family might need a GLP-1. How do I help?

For anyone helping a parent, partner or relative decide, and then supporting them through it.

GLP Guidebook teamUpdated Oct 12, 20264 min read14 sourcesWritten from published sources
The short answer

Read the basics together, talk without blame, and go to the appointment with them if they'd like you there. Weight is driven by genes and surroundings, not just willpower. GLP-1 medicines are usually long-term. Who pays depends on their coverage: an employer plan, Medicare's temporary $50 GLP-1 Bridge, their state's Medicaid, or the makers' self-pay prices. Older parents need extra care with fluids, low sugar and muscle.

Read this page first. It covers how to bring it up, who pays, what to watch for in an older parent and how to prepare for the appointment. At the end, three guides take you further, in order.
On this page
  1. Talking without shame
  2. Who pays, and for how long
  3. An older parent
  4. Going to the appointment
  5. The risks, in brief
  6. What to read next
  7. Sources

How do I bring it up without shame?

Talk about health and how they feel, not how they look. And drop the blame.

A group of international experts agreed that obesity is not a choice.1 It comes mainly from genes and the world around us.1

Shame also backfires. People who fear being judged are less likely to seek care.1

  • Avoid words like "lazy" or "greedy", even as a joke. The experts' pledge rejects them.1
  • Start from what they care about: energy, knees, sugar levels, keeping up with grandchildren.
  • Ask "How can I help?" rather than telling them what to do.
  • Ask before you share their health with other relatives.

Who pays, and for how long?

Plan for a cost that may run for years, not weeks.

Most of the weight usually returns after stopping. In a follow-up of the main semaglutide 2.4 mg (Wegovy) trial, people regained about two-thirds of it within a year of stopping.2 So agree early who pays, and for how long.

  • An employer or private plan: coverage for weight loss is optional, and usually needs prior authorization. 19% of firms with 200 or more workers covered GLP-1s mainly for weight loss in 2025.3
  • Medicare (most people 65 and over): by law it can't cover medicines for weight loss alone. The temporary Medicare GLP-1 Bridge charges $50 a month for Wegovy, the Zepbound KwikPen or Foundayo, from July 2026 to December 2027, for people who meet its BMI and health criteria. Medicare drug plans can cover GLP-1s for type 2 diabetes, heart protection or sleep apnea.4,5
  • Medicaid: each state decides; 13 states covered GLP-1s for obesity in January 2026.6
  • Paying yourselves: the makers' own self-pay prices run from $149 to $449 a month, depending on brand and dose (checked Oct 12, 2026). Their savings cards can't be used with Medicare or Medicaid.7

Guide 6 explains each route, and the cost calculator works out a year's total.

What should I watch for in an older parent?

Older adults do take these medicines. Watch three things closely: fluids, low sugar and muscle.

In the main Ozempic trials, 744 people, about 1 in 4 of those taking part, were 65 or older. No overall differences in safety or effect were seen between older and younger people.8 In the large Wegovy heart trial, people aged 75 and over had more hip and pelvis fractures on Wegovy than on a dummy injection: 24 in 1,000 against 6 in 1,000.13

  • Fluids. Vomiting or diarrhea can dry them out and harm the kidneys.8 Check they're drinking enough, especially in hot weather or when they're unwell.
  • Low sugar. If they take insulin or a sulfonylurea (an older type of diabetes pill), the risk of low blood sugar goes up.8 Learn the signs: dizziness, sweating, shakiness, confusion.8
  • Muscle. Part of the weight lost is lean mass (everything that isn't fat, including muscle), and older age raises the risk of muscle loss (sarcopenia).9 Ask the doctor about protein and safe exercise.
  • Other pills. These medicines slow the stomach, which can change how other pills are absorbed.8 Keep a full list of everything they take.

Should I go to the appointment with them?

If they'd like you there, yes. A second pair of ears helps, and you'll both hear the same advice.

Know who's prescribing. All GLP-1 medicines need a prescription from a prescriber licensed in their state, in person or by telehealth.10 Make sure the medicine is an FDA-approved brand: compounded versions sold online are not FDA-approved.11

Take with you

  • A list of all their medicines, including supplements and anything bought online
  • Their insurance or Medicare card
  • Recent results: HbA1c, kidney tests, blood pressure readings
  • "Which medicine and dose, and why this one?"
  • "Which side effects should we call you about?"
  • "Is it covered, does it need prior authorization, and what will each month cost?"
If they have diabetesShould they consider it?Cost calculator

What to read next, in order

These three guides go deeper. Each one ends with a link to the next, so you can read them one after another.

  1. 1Weight and health: what BMI and waist numbers meanGuide 1 of 9UnderstandUnderstand their numbers first: BMI, waist size, and the CDC categories.
  2. 2Should I consider a GLP-1? And when not toGuide 4 of 9DecideWho prescribers may consider for a GLP-1, and the reasons not to, including age and kidneys.
  3. 3Side effects and risksGuide 5 of 9DecideKnow the side effects together, so you both know which ones need help fast.
Was this page easy to understand?

Sources

  1. Rubino F et al. Joint international consensus statement for ending stigma of obesity. Nature Medicine, 2020;26:485–497. Statements 6.2 and 10.3, and Box 1. Declared interests: 15 of 36 authors declare ties to Novo Nordisk and 2 to Eli Lilly; Novo Nordisk was one of the sponsors of the meeting's travel costs (paper's own declaration). Full text
  2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–1564. 327 people followed for a year after stopping. DOI
  3. KFF. 2025 Employer Health Benefits Survey (19% of firms with 200 or more workers cover GLP-1s primarily for weight loss; typically with prior authorization). kff.org
  4. KFF. Nearly four million Medicare beneficiaries met the eligibility criteria in 2023 for the Medicare GLP-1 Bridge (statutory prohibition unchanged; Part D covers GLP-1s for diabetes, sleep apnea and MASH). June 29, 2026. kff.org
  5. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: information for prescribers. Product No. 12235, June 2026. cms.gov
  6. KFF. Medicaid coverage of and spending on GLP-1s (13 states as of January 2026). January 16, 2026. kff.org
  7. Makers' self-pay prices and savings-card terms, checked October 12, 2026: Novo Nordisk, NovoCare Wegovy self-pay offer; Eli Lilly, Zepbound and Foundayo coverage and savings pages (government beneficiaries excluded from savings cards). NovoCare · Zepbound · Foundayo
  8. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised May 2026. Sections 4, 5.3, 5.5, 5.6, 7.2, 8.5. PDF
  9. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024;26(Suppl 4):16–27. DOI
  10. American Medical Association. How state licensing has evolved to meet telehealth's challenges. October 12, 2023. ama-assn.org
  11. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
  12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021;384:989–1002. 1,961 adults without diabetes, 68 weeks. DOI
  13. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026. Sections 1, 5, 6.1 (fractures), 8.3. PDF
  14. America's Poison Centers. Poison Control: 1-800-222-1222. Checked October 12, 2026. poison.org

Last checked Oct 12, 2026 · Next review due Jan 2027

How this page was made. Written by the GLP Guidebook team from the sources above: drug labels, published trials, a consensus statement, and CMS, KFF and FDA pages. It's general information, not medical advice. Talk to a doctor or another qualified prescriber before starting, stopping or changing any medicine. In an emergency, call 911. How we write